A new premium version of Reaxys® for research intensive
institutions.
Frankfurt, Germany - Elsevier,
a world-leading provider of scientific, technical and
medical information products and services, today announced
the launch of Reaxys Xcelerate™, a premium version of
Reaxys® developed in close consultation with research
intensive organizations. Reaxys Xcelerate™ further
extends the capabilities of Reaxys®, a leading workflow
solution that provides extensive information on chemical
compounds and reactions.
Reaxys Xcelerate™ has been designed to streamline research
intensive chemistry workflows for:
-
Synthetic chemists who need to view and analyze numerous
potential retrosynthetic pathways can get immediate,
automated, multiple synthetic plans, complete with access
to the necessary background data, ensuring they can make
informed decisions about the most effective routes to
take to the lab.
-
Chemistry researchers who need to compare and contrast
multiple datasets can utilize Reaxys Xcelerate's
intelligent results visualization, reducing data analysis
complexity. Context sensitive graphical overviews and the
ability to cluster results for maximum relevance enables
immediate insights, which speeds up the analysis
process.
- Global teams and diverse research groups who need to share information across labs and geographies can use enhanced information exchange capabilities. Researchers can pinpoint the exact area of interest, annotate with further insights or instructions and share instantly with colleagues for more effective teamwork.
"Working closely with our partners, we identified and
invested in a number of new tools to support research
intensive workflows," said Mark van Mierle, Managing
Director of Elsevier's Pharma and Biotech Group. "For
organizations in competitive research environments, whether
at corporations developing new materials, pharmaceutical
organizations developing potential drugs, or academic
institutions conducting groundbreaking research Reaxys
Xcelerate™ provides a step change in individual and
organizational productivity."
Reaxys® and Reaxys Xcelerate™ follow the same agile
development process, ensuring that the two versions
continue to deliver the relevant content and insights
needed by research chemists. To find out more about Reaxys
Xcelerate™, including the opportunity to experience the
product, visit www.reaxys.com/info/xcelerate.
Reaxys ® and the Reaxys trademark are owned and protected
by Elsevier Properties SA and used under license.
# # #
About Elsevier
Elsevier is a world-leading provider of scientific,
technical and medical information products and services.
The company works in partnership with the global science
and health communities to publish more than 2,000 journals,
including The
Lancet and Cell, and close to
20,000 book titles, including major reference works from
Mosby and Saunders. Elsevier's online solutions include SciVerse
ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and
Nursing Consult, which enhance the productivity of
science and health professionals, and the SciVal suite and MEDai's Pinpoint Review,
which help research and health care institutions deliver
better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading
publisher and information provider, which is jointly owned
by Reed Elsevier PLC and Reed Elsevier NV. The ticker
symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1 215 239 3508
t.reller@elsevier.com
distribué par | Ce noodl a été diffusé par Reed Elsevier plc et initialement mise en ligne sur le site http://www.reed-elsevier.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-30 16:23:39 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |